

Explore Our Active Clinical Trials*

Tap on a trial to learn more



Investigating Established Agents in New Treatment Areas or Settings

BRENTUXIMAB VEDOTIN^a

Diffuse large B-cell lymphoma
ECHELON-3 | 3L+

Early and advanced stage Hodgkin lymphoma
SGN35-027 | 1L

CD30-low and -negative peripheral T-cell lymphoma
SGN35-032 | 1L

Metastatic non-small cell lung cancer, melanoma, and squamous cell carcinoma of the head and neck
SGN35-033 | 1L, 2L

AYA CD30+ Hodgkin lymphoma
CHECKMATE 744 | 2L

ENFORTUMAB VEDOTIN^b

Locally advanced or metastatic urothelial cancer
EV-302/KEYNOTE-A39^c | 1L

Cisplatin-ineligible/decline cisplatin muscle invasive bladder cancer
KEYNOTE-905/EV-303^d | Perioperative

Cisplatin-eligible muscle invasive bladder cancer
KEYNOTE-B15/EV-304^d | Perioperative

Locally advanced or metastatic solid tumors
EV-202 | 2L+

Locally advanced or metastatic urothelial cancer
KEYMAKER-U04^e | 1L

Urothelial cancer
EV-103/KEYNOTE-869^f | Various settings

BCG-unresponsive non-muscle invasive bladder cancer
EV-104 | Intravesical EV

TUCATINIB

HER2+ breast cancer
CompassHER2 RD^g | EBC

HER2+ breast cancer
HER2CLIMB-02 | 2L

HER2+ breast cancer
HER2CLIMB-05^h | 1L

HER2+ colorectal cancer
MOUNTAINEER-03^h | 1L

HER2+ breast cancer
HER2CLIMB-04 | 2L+

Locally advanced or metastatic solid tumors with HER2 alterations
SGNTUC-019 | 2L+

HER2+ gastrointestinal cancers
SGNTUC-024 | 1L+

TISOTUMAB VEDOTINⁱ

Recurrent or metastatic cervical cancer
innovaTV 301 | 2L+

Advanced solid tumors
innovaTV 207^j | 1L, 2L+

Recurrent or metastatic cervical cancer
innovaTV 205^j | 2L+

Late-Stage ADCs

DISITAMAB VEDOTIN

Locally advanced or metastatic urothelial cancer with HER2 expression
SGNDV-001^k | 1L

Locally advanced or metastatic urothelial cancer with HER2 expression
RC48 G001^l | 2L+

Locally advanced or metastatic tumors with HER2 expression
SGNDV-005 | 2L+

Locally advanced or metastatic breast cancer and gastric cancer with HER2 expression
SGNDV-004 | 2L+

SGN-B6A

Previously treated non-small cell lung cancer
SGNB6A-002 | 2L+

Advanced solid tumors
SGNB6A-001 | 1L/1L+

Early-Stage ADCs

SGN-35T

Lymphomas
SGN35T-001 | 2L+

Advanced solid tumors
SGNB7H4V-001 | 2L+

Advanced solid tumors
SGNCEA5C-001 | 2L+

Advanced solid tumors
SGNPD1V-001 | 2L+

SGN-PDL1V

Advanced solid tumors
SGNPD1V-001 | 2L+

Other Targeted Modalities

SGN-BB228

Advanced melanoma and solid tumors
SGNBB228-001 | 2L+

SGN-EGFRd2

Advanced solid tumors
SGNEGFRd2-001 | 2L+

SEA-CD70

Myelodysplastic syndrome and acute myeloid leukemia
SGNS70-101 | 1L+

Seagen technology

- Antibody-drug conjugate (ADC)
- Small molecule

- Bispecific antibody
- Sugar-engineered antibody (SEA)

Line of therapy

1L: first line | 2L: second line | 3L: third line

Trial phase

1 2 3

*The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

AYA: adolescents and young adults; BCG: bacillus Calmette-Guérin; CD: cluster of differentiation; EBC: early breast cancer; HER2: human epidermal growth factor receptor 2
^aProgram being co-developed with Takeda Pharmaceutical Company, Ltd.; ^bProgram being co-developed with Astellas Pharma Global Development, Inc.; ^cStudy sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD). Enrolling in a China-specific extension only; ^dStudy sponsored by MSD, in collaboration with Seagen Inc. and Astellas Pharma Global Development, Inc.; ^eStudy sponsored by MSD; Substudy 04B of KEYMAKER-U04 umbrella study; ^fStudy sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and MSD; ^gTrial being conducted by the Alliance for Clinical Trials in Oncology; ^hTrial being co-developed with MSD; Program being co-developed with Genmab A/S; ⁱTrial in collaboration with MSD; ^jTrial in collaboration with RemeGen Co., Ltd. and MSD
 Seagen and its logo are US registered trademarks of Seagen Inc. Other trademarks are property of their respective owners.
 © 2024 Seagen Inc., Bothell, WA 98021. All rights reserved. USM/PPL/2024/0004. MA-MM-06973